PDF(Sci-hub)
Abstract：
Even though the results of current therapy are improved for B-cell acute lymphoblastic leukemia (B-ALL) and Burkitt\'s lymphoma (BL), prognosis of relapsed mature B-ALL and BL still remain extremely poor. In this study, we investigated the possibility of applying the use of non-radiolabelled PCR consensus primers and automatic sequencing for the rapid identification of the tumor-specific V(H) CDR3 nucleotide sequence, in mature B-ALL and BL. RNA was extracted from four consecutive, unselected samples from BL cases and three consecutive, unselected samples from mature B-ALL cases. The feasibility of the identification of the tumor-specific V(H) CDR3 nucleotide sequence was then assessed by using non-radiolabelled PCR consensus primers with automatic sequencing. The tumor-specific V(H) CDR3 nucleotide sequence was successfully identified for all seven patients (3 mature B-ALL and BL). The time required was substantially lower than that of the other methods previously published, despite the poor quality of some of the samples. The procedure showed rapidity, reliability and reproducibility. The characteristics of the methodology applied widen the possibility of developing anti-idiotypic therapeutic strategies, even in these B-cell malignancies.
摘要：
尽管目前治疗B细胞急性淋巴细胞白血病（B-ALL）和伯基特淋巴瘤（BL）的结果有所改善，复发成熟B-ALL和BL的预后仍然极差。在这项研究中,我们研究了使用非放射性标记的PCR共有引物和自动测序来快速鉴定肿瘤特异性V（H）CDR3核苷酸序列的可能性。在成熟的B-ALL和BL中。从四个连续的RNA中提取，来自BL病例的未选择样本和三个连续样本，来自成熟B-ALL病例的未选择样本。然后通过使用具有自动测序的非放射性标记的PCR共有引物来评估鉴定肿瘤特异性V(H)CDR3核苷酸序列的可行性。对于所有7名患者(3名成熟B-ALL和BL)成功鉴定了肿瘤特异性V(H)CDR3核苷酸序列。所需的时间大大低于以前发表的其他方法，尽管一些样品质量差。程序显示了速度，可靠性和再现性。所应用的方法的特征扩大了开发抗独特型治疗策略的可能性，甚至在这些B细胞恶性肿瘤中。
